Union européenne - français - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozine - diabète sucré, type 2 - les médicaments utilisés dans le diabète - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 et 5.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - canagliflozinum - comprimés pelliculés - canagliflozinum 100 mg ut canagliflozinum hemihydricum, cellulosum microcristallinum, lactosum 39.26 mg, carmellosum natricum conexum corresp. natrium 0.84 mg, hydroxypropylcellulosum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (flavum), pro compresso obducto. - antidiabétique oral utilisé - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - canagliflozinum - comprimés pelliculés - canagliflozinum 300 mg ut canagliflozinum hemihydricum, cellulosum microcristallinum, lactosum 117.78 mg, carmellosum natricum conexum corresp. natrium 2.52 mg, hydroxypropylcellulosum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, pro compresso obducto. - antidiabétique oral utilisé - synthetika

Canada - français - Health Canada

janssen inc - canagliflozine - comprimé - 100mg - canagliflozine 100mg - sodium-glucose cotransporter 2 (sglt2) inhibitors

Canada - français - Health Canada

janssen inc - canagliflozine - comprimé - 300mg - canagliflozine 300mg - sodium-glucose cotransporter 2 (sglt2) inhibitors